Md Saiful Islam Khan/iStock via Getty Images Agenus ( NASDAQ: AGEN ) shares traded higher on Friday after the company updated data from a Phase 1b trial for its colorectal cancer drug therapy, botensilimab plus balstilimab (BOT/BAL), developed in partnership with Ligand Pharmaceuticals ( NASDAQ: LGND ). The analysis was based on 77 patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) who had no active liver metastases (NLM). Citing NLM data, the company said that the drug combo led to an overall response rate (ORR) of 18%–33% and a disease control rate of 67%–82% in the patient population who had received a median of four prior lines of therapy.
There were no new safety signals. Early this year, a March 1 data cut indicated that BOT/BAL led to an ORR of 23% following a median follow-up of 13.6 months.
More on Agenus, Ligand Pharma, etc. Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript Ligand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call Presentation Agenus Inc. (AGEN) Q1 2024 Earnings Call Transcript Ligand Pharmaceuticals Non-GAAP EPS of $1.
20 beats by $0.37, revenue of $30.98M beats by $3.
06M Ligand Pharmaceuticals and Agenus enter into royalty financing deal.
